Belantamab mafodotin (multiple myeloma) - Addendum to Commission G20-22

Report documents

1. Addendum

   Belantamab mafodotin (multiple myeloma) - Addendum to Commission G20-22

   published on

   04.03.2021

   Document type

   PDF document, 140 kB, DE, not accessible

   Download file : Addendum (PDF document, 140 kB, DE, not accessible)

Additional information

Project details

Project no.

G21-05

Commission

Commission awarded on 27.01.2021 by the Federal Joint Committee (GBA).

Report type

Addendum

Status

Commission completed

Department/Division

Health Economics

Topic

Cancer

Note

If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.

Connected Projects

1. Dossier assessment

   Belantamab mafodotin (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

   Project no.

   G20-22

   Last updated

   04.03.2021

   Status: Commission completed